Stoke Therapeutics Inc (STOK)

Jan 8, 2025, 4:30 PM EST - 9 days ago

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:00 AM EST - 10 days ago

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Jan 6, 2025, 4:30 PM EST - 11 days ago

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

Dec 6, 2024, 12:00 PM EST - 6 weeks ago

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Dec 5, 2024, 8:30 AM EST - 6 weeks ago

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

BIIB PRAX WGS

Dec 4, 2024, 7:00 AM EST - 6 weeks ago

Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome

Dec 2, 2024, 8:00 AM EST - 6 weeks ago

Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting

Nov 5, 2024, 7:00 AM EST - 2 months ago

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Sep 10, 2024, 7:00 AM EDT - 4 months ago

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome

Sep 7, 2024, 4:03 AM EDT - 4 months ago

Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome

Sep 4, 2024, 8:00 AM EDT - 4 months ago

Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

Sep 3, 2024, 8:00 AM EDT - 4 months ago

Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Sep 3, 2024, 8:00 AM EDT - 4 months ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in September

Aug 16, 2024, 4:30 PM EDT - 5 months ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Aug 7, 2024, 7:00 AM EDT - 5 months ago

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

Jun 24, 2024, 3:32 AM EDT - 7 months ago

Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday

EPAC OMIC ITI XAIR

Jun 14, 2024, 12:10 PM EDT - 7 months ago

Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome

Jun 3, 2024, 4:30 PM EDT - 8 months ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

May 6, 2024, 7:00 AM EDT - 9 months ago

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

Apr 29, 2024, 8:00 AM EDT - 9 months ago

Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer

Apr 17, 2024, 8:00 AM EDT - 9 months ago

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

Apr 4, 2024, 4:30 PM EDT - 10 months ago

Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 27, 2024, 11:40 PM EDT - 10 months ago

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

Mar 26, 2024, 4:07 PM EDT - 10 months ago

Stoke Therapeutics Announces Proposed Public Offering

Mar 25, 2024, 4:01 PM EDT - 10 months ago

Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome

Mar 25, 2024, 4:01 PM EDT - 10 months ago

Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Jan 8, 2024, 8:00 AM EST - 1 year ago

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024

Jan 4, 2024, 4:30 PM EST - 1 year ago

Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 1, 2023, 9:00 AM EST - 1 year ago

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting

Nov 21, 2023, 8:00 AM EST - 1 year ago

Stoke Therapeutics to Present Data from the Company's Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting

Sep 21, 2023, 8:00 AM EDT - 1 year ago

Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

Sep 20, 2023, 4:30 PM EDT - 1 year ago

Stoke Therapeutics Appoints Ian Smith to its Board of Directors

Sep 10, 2023, 5:08 PM EDT - 1 year ago

Stoke Therapeutics Is Unable To Derisk Its Platform

Sep 5, 2023, 7:00 AM EDT - 1 year ago

Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress

Aug 2, 2023, 8:00 AM EDT - 1 year ago

Stoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

Jul 25, 2023, 7:00 AM EDT - 1 year ago

Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome

Jul 21, 2023, 7:30 AM EDT - 1 year ago

Stoke Therapeutics to Host Webinar to Present New Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome

May 3, 2023, 8:00 AM EDT - 1 year ago

Stoke Therapeutics to Present at the BofA Securities Health Care Conference

Apr 25, 2023, 7:00 AM EDT - 1 year ago

Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom

Mar 15, 2023, 7:00 AM EDT - 2 years ago

Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome

Mar 6, 2023, 7:00 AM EST - 2 years ago

Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Feb 27, 2023, 4:30 PM EST - 2 years ago

Stoke Therapeutics to Participate at Upcoming March Investor Conferences

Feb 12, 2023, 5:17 AM EST - 2 years ago

Stoke Therapeutics Looks Unfairly Valued

Feb 7, 2023, 8:00 AM EST - 2 years ago

Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference

Jan 9, 2023, 8:00 AM EST - 2 years ago

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023

Jan 4, 2023, 9:00 AM EST - 2 years ago

Nuvig Therapeutics Appoints Julie Smith Chief Executive Officer

EXEL

Jan 4, 2023, 8:00 AM EST - 2 years ago

Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 2, 2022, 9:00 AM EST - 2 years ago

Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

Nov 29, 2022, 7:30 AM EST - 2 years ago

Stoke Therapeutics to Present Data from the Company's Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting

Nov 28, 2022, 6:38 AM EST - 2 years ago

Buy Stoke Therapeutics At A Deep Discount Following Early Data In Dravet Syndrome